FDA Brief

Warning letters Food

FDA warning letter to

Quicksilver Scientific

LowIssued Oct 13, 2021Posted Nov 9, 2021Office of Human and Animal Food Operations Division West 4

FDA warned Quicksilver Scientific that website claims made four products unapproved new drugs and misbranded.

What happened

FDA reviewed Quicksilver Scientific’s website in June and September 2021 and found it took orders for Nanoemulsified Milk Thistle, Cat’s Claw Elite, Nanoemulsified CoQ10, and Liposomal GABA with L Theanine. The website included claims that these products treat, mitigate, or prevent diseases. FDA said this makes them unapproved new drugs and misbranded because they lack adequate directions for use.

What FDA found

  1. Website claims show the four products are intended to cure, mitigate, treat, or prevent disease, so FDA treats them as drugs.

    section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. § 321(g)(1)(B)]
  2. The products are not generally recognized as safe and effective for those uses and lack FDA approval, so they are unapproved new drugs.

    sections 201(p), 301(d), and 505(a) [21 U.S.C. §§ 321(p), 331(d), 355(a)]
  3. The products do not bear adequate directions for a layperson to use them safely for their intended uses, so they are misbranded.

    section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  4. Selling or shipping these misbranded drugs in interstate commerce violates the Act.

    section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the steps taken to address the violations, including steps to prevent recurrence and related documentation. If corrective actions cannot be completed in that time, the company must explain the delay and when it will finish.

Who should pay attention

  • dietary supplement companies that make disease-related website claims
  • online sellers of supplement or botanical products
  • marketers reviewing product web pages and blogs for drug claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk